Last reviewed · How we verify

NCT04826718

SARS-CoV-2/COVID-19 Infection Among Health Care Workers

Completed Last updated 9 June 2023
What this trial tests

trial testing Questionaire in SARS-CoV-2 in 400 participants. Completed in 31 January 2023.

Timeline
1 July 2021
Primary endpoint
8 September 2021
31 January 2023

Quick facts

Lead sponsorUniversidade de Cabo Verde
StatusCompleted
Study typeOBSERVATIONAL
Enrollment400
Start date1 July 2021
Primary completion8 September 2021
Estimated completion31 January 2023
Sites1 location across Cabo Verde

Drugs / interventions tested

Conditions studied

Sponsor

Universidade de Cabo Verde

Who can join

18 and older, any sex, with SARS-CoV-2 or BCG. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study finds opportunities and justifications, taking into consideration that the nature of professional practice in health needs scientific evidence resulting from systematic and systemic studies to strengthen the basis for the decisions made to have an impact on various levels, from the patient to health management itself. In addition, Cabo Verdean authorities may benefit from new evidence obtained by this study. It intends, in a growing number of health professionals exposed or infected with SARS-CoV-2, in the different health structures of the country, to contribute to substantiate a better perception of the problem and the required solutions. Therefore, assessing the potential risk factors for SARS-CoV-2 infection among healthcare workers will be essential to characterize virus transmission, preventing future infections in them and providing the associated healthcare. Due to the advances and important changes described, questions arise that guide this research and allow us to identify the problem.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19.
    Du J, Su Y, Wang R, Dong E, et al · · 2023 · cited 6× · PMID 36798128 · DOI 10.3389/fimmu.2023.1118378

Verify or expand the search:

Other trials of Questionaire

Trials testing the same drug.

Other recruiting trials for SARS-CoV-2

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04826718.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing